1. BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance.
- Author
-
Parker, W T, Yeoman, A L, Jamison, B A, Yeung, D T, Scott, H S, Hughes, T P, and Branford, S
- Subjects
CHRONIC myeloid leukemia ,GENETIC mutation ,IMATINIB ,DRUG resistance in cancer cells ,LONGITUDINAL method ,AMINO acid sequence - Abstract
Background:BCR-ABL1 mutation analysis is recommended for chronic myeloid leukaemia patients. However, mutations may become undetectable after changing therapy, and it is unknown whether they have been eradicated.Methods:We examined longitudinal data of patients with imatinib-resistant mutations, which became undetectable by Sanger sequencing to determine whether mutations could reappear, and the related circumstances.Results:Identical imatinib- and nilotinib-resistant mutations reappeared following further therapy changes in five patients, and was associated with subsequent nilotinib resistance in four.Conclusion:The data suggest that some BCR-ABL1 mutations may persist at undetectable levels for many years after changing therapy, and can be reselected and confer resistance to subsequent inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF